Literature DB >> 7660065

Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7.

S Bauer1, K Heeg, H Wagner, G B Lipford.   

Abstract

Peptides can be used to induce MHC class I restricted cytotoxic T cells (CTL) through in vivo immunization. This approach may enable the development of peptide vaccination schemes for immunization against viral infection in humans. Human papillomavirus (HPV) is one of a few viruses associated with human cancer and the development of an anti-cancer vaccine seems possible. As a model approach, we searched the E6 and E7 proteins of the human papillomavirus type 16 for possible murine MHC class I restricted peptide epitopes. We utilized the mouse H2-Kb peptide binding motif which consists of phenylalanine or tyrosine at position five and leucine at the carboxy-terminus with the modification that leucine could be replaced by other aliphatic but non-aromatic amino acids. Four peptide sequences from E6 and two from E7 were selected. These peptides were tested for their ability to bind and stabilize Kb and for their immunogenicity in vivo. It was shown that one peptide from E6, E6.1 (50-57), bound Kb, but was not able to prime mice in vivo. In contrast, the two selected E7 peptides E7.1 (21-28) and E7.2 (48-55) bound Kb and were immunogenic in vivo. The peptide induced CTL lysed syngeneic EL-4 cells transfected with the open reading frame of E7 but not vector only transfectants. This implies that both peptides were naturally processed and presented by Kb on the surface of target cells. MHC class I peptide binding motifs therefore appear to be an effective and useful tool to predict peptide epitopes of proteins associated with cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7660065     DOI: 10.1111/j.1365-3083.1995.tb03662.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  8 in total

1.  Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.

Authors:  Shiwen Peng; Hongxiu Ji; Cornelia Trimble; Liangmei He; Ya-Chea Tsai; Jessica Yeatermeyer; David A K Boyd; Chien-Fu Hung; T-C Wu
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

2.  Recombinant HPV16 E7 assembled into particles induces an immune response and specific tumour protection administered without adjuvant in an animal model.

Authors:  Linda Petrone; Maria G Ammendolia; Armando Cesolini; Stefano Caimi; Fabiana Superti; Colomba Giorgi; Paola Di Bonito
Journal:  J Transl Med       Date:  2011-05-18       Impact factor: 5.531

3.  The CD8⁺ T Cell-Mediated Immunity Induced by HPV-E6 Uploaded in Engineered Exosomes Is Improved by ISCOMATRIXTM Adjuvant.

Authors:  Francesco Manfredi; Paola di Bonito; Barbara Ridolfi; Simona Anticoli; Claudia Arenaccio; Chiara Chiozzini; Adriana Baz Morelli; Maurizio Federico
Journal:  Vaccines (Basel)       Date:  2016-11-09

4.  Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation.

Authors:  Paola Di Bonito; Chiara Chiozzini; Claudia Arenaccio; Simona Anticoli; Francesco Manfredi; Eleonora Olivetta; Flavia Ferrantelli; Emiliana Falcone; Anna Ruggieri; Maurizio Federico
Journal:  Int J Nanomedicine       Date:  2017-06-23

5.  The C-Terminal Domain of Nefmut Is Dispensable for the CD8+ T Cell Immunogenicity of In Vivo Engineered Extracellular Vesicles.

Authors:  Chiara Chiozzini; Francesco Manfredi; Flavia Ferrantelli; Patrizia Leone; Andrea Giovannelli; Eleonora Olivetta; Maurizio Federico
Journal:  Vaccines (Basel)       Date:  2021-04-12

6.  Long-Term Antitumor CD8+ T Cell Immunity Induced by Endogenously Engineered Extracellular Vesicles.

Authors:  Flavia Ferrantelli; Francesco Manfredi; Chiara Chiozzini; Patrizia Leone; Andrea Giovannelli; Eleonora Olivetta; Maurizio Federico
Journal:  Cancers (Basel)       Date:  2021-05-08       Impact factor: 6.639

7.  HPV-E7 delivered by engineered exosomes elicits a protective CD8⁺ T cell-mediated immune response.

Authors:  Paola Di Bonito; Barbara Ridolfi; Sandra Columba-Cabezas; Andrea Giovannelli; Chiara Chiozzini; Francesco Manfredi; Simona Anticoli; Claudia Arenaccio; Maurizio Federico
Journal:  Viruses       Date:  2015-03-09       Impact factor: 5.048

8.  Simultaneous CD8+ T-Cell Immune Response against SARS-Cov-2 S, M, and N Induced by Endogenously Engineered Extracellular Vesicles in Both Spleen and Lungs.

Authors:  Flavia Ferrantelli; Chiara Chiozzini; Francesco Manfredi; Andrea Giovannelli; Patrizia Leone; Maurizio Federico
Journal:  Vaccines (Basel)       Date:  2021-03-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.